Free Trial

INSPECS Group (SPEC) Competitors

INSPECS Group logo
GBX 42 0.00 (0.00%)
As of 01/17/2025 12:18 PM Eastern

SPEC vs. BVC, AKR, CNSL, ODX, CTEC, AMS, TSTL, BVXP, 4BB, and ANCR

Should you be buying INSPECS Group stock or one of its competitors? The main competitors of INSPECS Group include BATM Advanced Communications (BVC), Akers Biosciences (AKR), Cambridge Nutritional Sciences (CNSL), Omega Diagnostics Group (ODX), ConvaTec Group (CTEC), Advanced Medical Solutions Group (AMS), Tristel (TSTL), Bioventix (BVXP), 4basebio (4BB), and Animalcare Group (ANCR). These companies are all part of the "medical" sector.

INSPECS Group vs.

INSPECS Group (LON:SPEC) and BATM Advanced Communications (LON:BVC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations, risk and community ranking.

In the previous week, BATM Advanced Communications had 4 more articles in the media than INSPECS Group. MarketBeat recorded 4 mentions for BATM Advanced Communications and 0 mentions for INSPECS Group. BATM Advanced Communications' average media sentiment score of 0.78 beat INSPECS Group's score of 0.00 indicating that BATM Advanced Communications is being referred to more favorably in the news media.

Company Overall Sentiment
INSPECS Group Neutral
BATM Advanced Communications Positive

67.8% of INSPECS Group shares are held by institutional investors. Comparatively, 42.4% of BATM Advanced Communications shares are held by institutional investors. 25.6% of INSPECS Group shares are held by insiders. Comparatively, 26.2% of BATM Advanced Communications shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

INSPECS Group has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500. Comparatively, BATM Advanced Communications has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

BATM Advanced Communications received 185 more outperform votes than INSPECS Group when rated by MarketBeat users. However, 100.00% of users gave INSPECS Group an outperform vote while only 49.22% of users gave BATM Advanced Communications an outperform vote.

CompanyUnderperformOutperform
INSPECS GroupOutperform Votes
5
100.00%
Underperform Votes
No Votes
BATM Advanced CommunicationsOutperform Votes
190
49.22%
Underperform Votes
196
50.78%

BATM Advanced Communications has lower revenue, but higher earnings than INSPECS Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£195.14M0.22-£4.11M-£3.07-13.68
BATM Advanced Communications£122.70M0.65£2.51MN/AN/A

INSPECS Group pays an annual dividend of GBX 1 per share and has a dividend yield of 2.4%. BATM Advanced Communications pays an annual dividend of GBX 1 per share and has a dividend yield of 5.5%. INSPECS Group pays out -32.6% of its earnings in the form of a dividend.

BATM Advanced Communications has a net margin of -0.21% compared to INSPECS Group's net margin of -2.11%. BATM Advanced Communications' return on equity of -0.17% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.11% -3.95% 0.45%
BATM Advanced Communications -0.21%-0.17%0.58%

Summary

BATM Advanced Communications beats INSPECS Group on 11 of the 16 factors compared between the two stocks.

Get INSPECS Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPEC vs. The Competition

MetricINSPECS GroupMedical Instruments & Supplies IndustryMedical SectorLON Exchange
Market Cap£42.70M£2.88B£5.21B£2.06B
Dividend Yield2.00%2.01%5.13%5.16%
P/E Ratio-13.68344.3089.801,943.78
Price / Sales0.22166.071,248.23427,090.66
Price / Cash1.63146.5443.8229.43
Price / Book0.423.015.323.10
Net Income-£4.11M£91.96M£122.69M£158.20M
7 Day Performance5.53%2.14%-0.17%3.24%
1 Month Performance-2.42%1.92%3.49%3.38%
1 Year Performance-54.95%-4.02%25.79%168.76%

INSPECS Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPEC
INSPECS Group
N/AGBX 42
flat
N/A-54.3%£42.70M£195.14M-13.681,673Gap Down
BVC
BATM Advanced Communications
N/AGBX 18.56
+0.6%
N/A-20.5%£80.97M£122.70M2,800.00980Analyst Forecast
News Coverage
Gap Down
AKR
Akers Biosciences
N/AN/AN/AN/A£21.64M£2.32M-0.44120
CNSL
Cambridge Nutritional Sciences
N/AGBX 3.06
+0.4%
N/A+73.6%£7.28M£9.77M-362.103,200News Coverage
ODX
Omega Diagnostics Group
N/AN/AN/AN/A£5.23M£7.55M-220.0091Gap Down
CTEC
ConvaTec Group
N/AGBX 226.80
+1.2%
GBX 301.67
+33.0%
-1.5%£4.65B£2.20B3,780.0010,000
AMS
Advanced Medical Solutions Group
2.402 of 5 stars
GBX 190.60
flat
GBX 300
+57.4%
+5.5%£408.93M£131.11M3,812.0010Analyst Forecast
News Coverage
TSTL
Tristel
N/AGBX 400
-5.7%
N/A-3.1%£190.60M£39.49M3,076.92208Gap Down
BVXP
Bioventix
N/AGBX 3,101
-5.9%
N/A-26.6%£161.87M£13.60M1,902.4512News Coverage
Gap Down
4BB
4basebio
N/AGBX 1,260
+0.2%
N/A+84.9%£161.41M£311,000.00-1,615.38101Gap Up
ANCR
Animalcare Group
N/AGBX 240
-2.0%
N/A+40.5%£144.89M£76.10M3,000.00220

Related Companies and Tools


This page (LON:SPEC) was last updated on 1/19/2025 by MarketBeat.com Staff
From Our Partners